CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Solifenacin succinate / tamsulosin hydrochloride

Last Updated: March 2, 2015
Result type: Reports
Project Number: SR0424-000
Product Line: Reimbursement Review

Generic Name: Solifenacin succinate / tamsulosin hydrochloride

Brand Name: VesiFlow

Manufacturer: Astellas Pharma Canada, Inc.

Therapeutic Area: Benign prostatic hyperplasia

Indications: Benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms

Submission Type: Initial

Project Status: Withdrawn